pocketful logo
Wockhardt Ltd logo

Wockhardt Ltd

NSE: WOCKPHARMA BSE: 532300

₹1175.70

(-1.16%)

Sun, 05 Apr 2026, 07:57 am

mtf coin illustrationMTF 5x

Wockhardt Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    20670.63

  • Net Profit

    -57

  • P/B

    5.30

  • Sector P/E

    31.02

  • P/E

    0

  • EV/EBITDA

    54.71

  • Debt/Equity (Industry)

    0.23

  • Interest Cover (Industry)

    9.71

  • ROCE (Industry)

    13

  • RONW (Industry)

    12.31

  • ROE

    -1.48

  • ROCE

    3.87

  • Debt/Equity

    0.57

  • EPS (TTM)

    7.66

  • Dividend Yield

    0

  • Book Value

    281.07

  • Interest Cover

    0.94

Analysis

all

thumbs up icon

Pros

  • Wockhardt has been profitable on average in the past, therefore cash runway is not a concern.
  • Wockhardt has been profitable on average in the past, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (33.1%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 1x debt.
  • Wockhardt's cash and other short term assets cover its long term commitments.
thumbs up icon

Cons

  • Unable to calculate sustainability of dividends as Wockhardt has not reported any payouts.
  • Unable to evaluate Wockhardt's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Wockhardt's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Wockhardt's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • The level of debt compared to net worth has increased over the past 5 years (30.7% vs 77.2% today).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters49.0849.0849.0949.0949.09
FII6.997.097.286.816.54
DII10.5511.0111.0110.599.82
Public33.3632.8032.6033.5034.54
Government0.020.020.020.020.02

Read More

Technical Analysis

RSI

52.15

MACD

-33.54

50 DMA

1317.67

200 DMA

1445.79

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1724.671463.971319.831203.271059.13942.57681.87
Fibonacci1463.971364.381302.851203.271103.681042.15942.57
Camarilla1247.391223.501199.601203.271151.801127.901104.01

Pivots Level: Classic

R3

+521.40

1724.67

R2

+260.70

1463.97

R1

+116.57

1319.83

1203.27
1203.27
Pivot Point
LTP: 1271.50

S1

-144.13

1059.13

S2

-260.70

942.57

S3

-521.40

681.87

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1216.66

  • 20-EMA

    1237.25

  • 30-EMA

    1261.39

  • 50-EMA

    1295.09

  • 100-EMA

    1340.56

  • 200-EMA

    1363.66

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
10 Feb 2026board-meetingsQuarterly Results
03 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
16 Jul 2025agm
05 Jun 2024agm
21 May 2024agmAnnual General Meeting21 Jun 2024
21 Jul 2023agm
07 Jul 2023agmAnnual General Meeting07 Aug 2023
21 Jul 2022agm
03 Mar 2022rights3:10 Rights Issue of Equity Shares09 Mar 2022
09 Feb 2022rightsRight Issue of Equity Shares09 Mar 2022

Read More

Peer Comparison

Wockhardt Ltd logo

Wockhardt Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Lupin Ltd logo

Lupin Ltd

Read More

Wockhardt Ltd About

Wockhardt is a global pharmaceutical and biotech company with presence in UK, Switzerland, Ireland, Russia and many other countries. It has manufacturing and research facilities in India & UK and a manufacturing facility in Ireland and Dubai. The Group has a significant presence in Europe and India.(Source : 202503-Annual Report Page No:95)

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1999

Headquarters

CEO

H F Khorakiwala

Employees

Contact

Website icon

Website

http://www.wockhardt.com

Email icon

Email

investorrelations@wockhardt.com

Phone icon

Phone

91-240-6694444

Location icon

Location

D-4 MIDC, Chikalthana, Aurangabad., Maharashtra, 431006

Read More

Wockhardt Ltd Company History

YearHistory
2018
  • Set up first manufacturing facility in Middle East for new chemical entities.
2019
  • Received US FDA approval for 100mg and 400mg tablets of Imatinib Mesylate.
  • Received US FDA approval for prostate cancer drug.
2020
  • Entered agreement with UK Government to fill-finish COVID-19 vaccines.
  • Received QIDP designation for combination antibiotic WCK 6777 from US FDA.
  • Received DCGI approval for 2 new antibiotics.
2021
  • Partnered with RDIF to produce Sputnik V and Sputnik Light vaccines against COVID-19.
  • Partnered with Jemincare for novel respiratory antibiotic Nafithromycin.
2022
  • Issued rights shares of Rs. 5 in the ratio of 3:10 at a premium of Rs. 220 per share.
  • Received affirmation in credit ratings from CARE.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPBuy844583456.7601 Jan 2024
GRAVITON RESEARCH CAPITAL LLPSell844583456.7201 Jan 2024
GRAVITON RESEARCH CAPITAL LLPSell979549397.2612 Dec 2023
GRAVITON RESEARCH CAPITAL LLPBuy979549397.1312 Dec 2023
GRAVITON RESEARCH CAPITAL LLPBuy916319373.2211 Dec 2023
GRAVITON RESEARCH CAPITAL LLPSell916319372.8311 Dec 2023
GRAVITON RESEARCH CAPITAL LLPSell1148101325.1717 Nov 2023
GRAVITON RESEARCH CAPITAL LLPBuy1148101324.8117 Nov 2023
AAKRAYA RESEARCH LLPBuy906544313.8716 Nov 2023
GRAVITON RESEARCH CAPITAL LLPBuy1808411307.0216 Nov 2023

Read More

Wockhardt Ltd News

Wockhardt's Zaynich Gets CDSCO Panel Nod

Wockhardt's novel antibiotic Zaynich (Zidebactam/Cefepime) receives favourable recommendation from CDSCO's Subject Expert Committee for treating Gram-negative infections, paving way for DCGI approval.

30 Mar 2026

companies

Wockhardt's Zaynich Gets CDSCO Panel Nod

Wockhardt's novel antibiotic Zaynich (Zidebactam/Cefepime) receives favourable recommendation from CDSCO's Subject Expert Committee for treating Gram-negative infections, paving way for DCGI approval.

30 Mar 2026

companies

Wockhardt Gets ESG Rating of 65 from NSE Analytics

Wockhardt Limited receives voluntary ESG rating of 65 (Aspiring) from NSE Sustainability Ratings for 2025, with scores of 51 for Environmental, 70 for Social, and 74 for Governance parameters.

19 Feb 2026

stocks

Wockhardt Q3FY26 QIP Monitoring Report Shows Progress

Wockhardt submitted Q3FY26 monitoring agency report showing Rs 26.60 crores utilization from QIP proceeds with no deviations from stated objectives.

10 Feb 2026

co actions results

Wockhardt's Foviscu Matches Meropenem in Phase 3 Trial

Wockhardt's novel antibiotic Foviscu achieved 93.23% clinical cure rate versus 92.31% with meropenem in Phase 3 trial for complicated urinary tract infections, becoming the company's fifth proprietary antibiotic to complete registration-enabling study.

27 Jan 2026

stocks

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800